At 8.9% CAGR, the Europe Glioma Treatment Market is projected to be worth US$ 1,905.10 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe glioma treatment market was valued at US$ 959.99 million in 2022 and is expected to reach US$ 1,905.10 million by 2030, registering a CAGR of 8.9% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing opportunities in emerging economies are among the critical factors attributed to the Europe glioma treatment market expansion.

The healthcare sector across the globe is projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

For instance, the creation of standardized data for risk assessment, technological advancement, more informed decision-making, and knowledge production is improving as a result of EU investments in R&D, innovation, and technology. For instance, it is possible to enhance clinical decision-making and therapy selection through the application of innovative medical technology in diagnostics. Each of these advancements makes the healthcare system more sustainable and economical. Thus, these investments in the healthcare sector in the region create opportunities for the glioma treatment market players to expand their business.

On the contrary, the high cost of diagnosis hampers the Europe glioma treatment market.

Based on disease, the Europe glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 72.4% share of Europe glioma treatment market in 2022, amassing US$ 695.19 million. It is projected to garner US$ 1,414.89 million by 2030 to expand at 9.3% CAGR during 2022–2030.

Based on treatment type, the Europe glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 45.5% share of Europe glioma treatment market in 2022, amassing US$ 436.56 million. It is projected to garner US$ 910.15 million by 2030 to expand at 9.6% CAGR during 2022–2030.

Based on grade, the Europe glioma treatment market is segmented into low grade and high grade. The high grade segment held 78.8% share of Europe glioma treatment market in 2022, amassing US$ 756.87 million. It is projected to garner US$ 1,527.14 million by 2030 to expand at 9.2% CAGR during 2022–2030.

Based on end user, the Europe glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 79.1% share of Europe glioma treatment market in 2022, amassing US$ 759.61 million. It is projected to garner US$ 1,518.67 million by 2030 to expand at 9.0% CAGR during 2022–2030.

Based on country, the Europe glioma treatment market has been categorized into France, Germany, Italy, Spain, the UK, and the Rest of Europe. Our regional analysis states that Germany captured 21.3% share of Europe glioma treatment market in 2022. It was assessed at US$ 204.40 million in 2022 and is likely to hit US$ 421.24 million by 2030, exhibiting a CAGR of 9.5% during 2022–2030.      

Key players operating in the Europe glioma treatment market are Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.   

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com